Sevuparin, a novel polysaccharide, acts by interfering with the harmful agents1 generated by white blood cells during systemic inflammation.  This interference can break the molecular chain of events that lead to vascular damage and plasma leakage in patients with sepsis/septic shock and other conditions where  systemic inflammation is involved. 

Sevuparin directly binds and neutralizes agents released from damaged white blood cells that are known to threaten vascular integrity. This activity has been shown in pre-clinical animal models, where sevuparin has been effective in protecting the blood vessels  and the lungs of mice.

1 Rasmuson et al, 2019

Further Reading

Non-anticoagulant effect of Heparin: An Overview. Handbook of Experimental Pharmacology. January 2020

Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. Plos One. May 2020

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients, EBio Medicine. August 2020

Heparinoid sevuparin inhibits Streptococcus‐induced vascular leak through neutralizing neutrophil‐derived proteins. FASEB Journal. June 2019